title: Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
abstract: Patients with nephrotic syndrome have multiple abnormalities of lipoprotein metabolism, but the cause and exact nature of these abnormalities have not been established. In the present study we have determined the kinetics of plasma low-density lipoprotein (LDL) apoB in seven nephrotic patients demonstrating an elevated LDL apoB production rate (25.7 +/- 6.4 vs. 13.1 +/- 0.3 mgkg-1 day-1; P < 0.001) but a normal LDL apoB fractional catabolic rate (FCR) (0.31 +/- 0.04 vs. 0.33 +/- 0.008 pools day-1; NS) compared with 41 healthy control subjects. However, two out of the seven patients had a markedly low LDL apoB-FCR. Serum albumin was inversely correlated with the LDL apoB production rate (R = -0.82; P < 0.05). Plasma lipoprotein (a) [Lp(a)] levels were significantly (P < 0.001) increased in the nephrotic patients compared with control subjects. Significant correlations were observed between log Lp(a) and LDL apoB production rate (R = 0.90; P < 0.01), VLDL-cholesterol (R = 0.95; P < 0.001) and VLDL-triglycerides (R = 0.80; P < 0.05) respectively. In summary, the present study suggests that nephrotic hyperlipidaemia may be caused by at least two independent mechanisms. The elevated LDL apoB production rate is highly correlated with the prevailing levels of serum albumin, whereas some nephrotic patients seem to have a decreased LDL apoB clearance, suggesting impaired LDL receptor-mediated clearance. The present results also suggest that the elevated plasma Lp(a) levels in nephrosis are related to an increased hepatic synthesis rather than a decreased catabolism of lipoproteins.
authors.affiliation: Department of Renal Medicine, Karolinska Institute at Huddinge University Hospital, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Stenvinkel
authors.forename: L
authors.initials: L
authors.lastname: Berglund
authors.forename: S
authors.initials: S
authors.lastname: Ericsson
authors.forename: A
authors.initials: A
authors.lastname: Alvestrand
authors.forename: B
authors.initials: B
authors.lastname: Angelin
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
mesh_terms: D000293:Adolescent; D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D007700:Kinetics; D017270:Lipoprotein(a) / Q000097:blood* / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood* / Q000209:etiology / Q000378:metabolism*; D011507:Proteinuria / Q000652:urine; D012044:Regression Analysis; D012709:Serum Albumin / Q000737:chemistry
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D012709:Serum Albumin; D002784:Cholesterol